LUX-LUNG 3 and 4 Show Afatinib Effective in EGFR-mutated NSCLC

Two new studies show that afatinib, an orally bioavailable ERBB family blocker, could be effective in patients with non–small-cell lung cancer (NSCLC) who progressed on other therapies and in patients with advanced lung adenocarcinomas and EGFR mutations.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news